What's in Medicines Evaluation Unit Ltd's pipeline?

Medicines Evaluation Unit Ltd has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Medicines Evaluation Unit Ltd's portfolio?

Top competitors by shared drug class: Eurofarma Laboratorios S.A..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/medicines-evaluation-unit-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Medicines Evaluation Unit Ltd — Portfolio Competitive Intelligence Brief

Medicines Evaluation Unit Ltd pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Fostair pMDI	Fostair pMDI	marketed
Trimbow pMDI	Trimbow pMDI	marketed	Triple combination inhaler (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor	Respiratory/Pulmonology

Therapeutic area mix

Respiratory/Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Eurofarma Laboratorios S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medicines Evaluation Unit Ltd:

Cite this brief

Drug Landscape (2026). Medicines Evaluation Unit Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medicines-evaluation-unit-ltd. Accessed 2026-05-14.